Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Santos, José R ^a,b   Muñoz Moreno, José A ^a,b   Moltó, José ^a,b   Prats, Anna ^a,b   Curran, Adrià ^c   Domingo, Pere ^d   Llibre, Josep M ^a,b   McClernon, Daniel R ^e   Bravo, Isabel ^a   Canet, Jaume ^a   Watson, Victoria ^f,g   Back, David ^f   Clotet, Bonaventura ^a,h  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e BioMONTR   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^h IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALE; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 84880800135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070201     Document Type: Article

References (49)

1. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3): 321-33.
2. EACS website. European AIDS Clinical Society (EACS). Guidelines. Clinical management and treatment of HIV-infected adults in Europe. October 6th 2011, version 6.0. Available: http://www.europeanaidsclinicalsociety.org. Accesed 2012 Oct 12.
3. AIDSinfo website. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2013 Jun 24.
4. Brinkman K, Hofstede H, Burger DM, Smeitink JA, Koopmans PP, (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12: 1735-44.
5. Hall AM, Hendry BM, Nitsch D, Connolly JO, (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57(5): 773-80.
6. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, et al. (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10(8): 482-7.
7. GESIDA website. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Updated January 2012). Available: http://www.gesida-seimc.org. Accesed 2012 Oct 12.
8. Valantin MA, Flandre P, Kolta S, Duvivier C, Algarte Genin M, et al. (2010) Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs+DRV/r in the MONOI-ANRS 136 Randomized Trial: Results at 48 weeks. 17th Conference on Retroviruses and Opportunistic Infections CROI 2010, February 16-19, 2010, San Francisco, USA. Poster O-262.
9. Kolta S, Flandre P, Van PN, Cohen-Codar I, Valantin MA, et al. (2011) Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. Curr HIV Res 9(1): 31-9.
10. Escobar I, Pulido F, Pérez E, Arribas JR, García MP, et al. (2006) Análisis farmacoeconómico de una estrategia de mantenimiento con lopinavir/ritonavir como monoterapia en pacientes con infección por el VIH. Enferm Infecc Microbiol Clin 24(8): 490-4.
11. Moltó J, Santos JR, Negredo E, Miranda C, Videla S, et al. (2007) Lopinavir/ritonavir monotherapy as simplification strategy in routine clinical practice. J Antimicrob Chemother 60(2): 436-9.
12. Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, et al. (2008) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22: F1-F9.
13. Bierman W, van Agtmael M, Nijhuis M, Danner SA, Boucher CA, (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23: 279-91.
14. Letendre S, McClernon D, Ellis R, Muñoz-Moreno J, Way L,et al. Persistent HIV in the Central Nervous System During Treatment is Associated with Worse Antiretroviral Therapy Penetration and Cognitive Impairment. The 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Poster 484b.
15. Letendre S, Ellis R, Ances B, McCutchan JA, (2010) Neurologic Complications of HIV Disease and Their Treatment. Top HIV Med 18(2): 45-55.
16. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, et al. (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25: 357-365.
17. Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, et al. (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24: 2347-2354.
18. McClernon AM, John WS, McClernon DR (2011) New HIV-1 SuperLow Assay for Viral Load Monitoring. Association of Molecular Pathology. 16-20th November 2011, Grapevine, Texas. Poster # ID13.
19. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM, (2003) Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 32(3): 287-91.
20. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18): 1789-99.
21. Muñoz-Moreno JA (2007) Neurocognitive and Motor Disorders in HIV Infection. Assessment and Interventions. In: Valerie N Plishe, Editor. Research Focus on Cognitive Disorders. Hauppauge, New York: Nova Science Publishers, Inc.
22. Weschler D (1997) Administration and scoring manual. Wechsler Adult Intelligence Scale - Third Edition (WAIS-III). San Antonio, TX: The Psychological Corporation.
23. Reitan RM, Davidson LA (1974) Clinical Neuropsychology: Current Status and Applications. New York, NY: John Wiley & Sons.
24. Smith A (1973) Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services.
25. Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test. New York, NY: The Psychological Corporation.
26. Golden CJ (1978) Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Wood Dale, IL: Stoetling Company.
27. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtis G (1993) Wisconsin Card Sorting Test (WCST) Manual Revised and Expanded. Odessa, FL: Psychological Assessment Resources.
28. Culbertson WC, Zillmer EA (2001) Tower of London-Drexel University (TOLDX). Toronto, Canada: Multi- Health Systems Inc.
29. Benton AL, Hamsher K, Sivan AB (1994) Multilingual Aphasia Examination. Iowa City: AJA Associates.
30. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, et al. (1999) Norms for letter and category fluency: Demographic corrections for age, education, and ethnicity. Assessment 6: 147-178.
31. Matthews CG, Klove H (1964) Instruction Manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School.
32. Wechsler D (1999) Escala de Inteligencia Wechsler para Adultos (WAIS-III) (3a Ed.). Madrid: TEA Ediciones.
33. Smith A (2002) Test de Símbolos y Dígitos (SDMT). Madrid: TEA Ediciones.
34. Reitan RM, Wolfson D (1985) Trail Making Test. The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
35. Golden CH (2001) Stroop. Test de Colores y Palabras. Madrid: TEA Ediciones.
36. Reitan RM, Wolfson D (1985) Grooved Pegboard. The Halstead-Reitan Extended Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
37. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, et al. (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26(3): 307-19.
38. Beck AT, Rush AJ, Shaw BF, Emery G (1979) Cognitive Therapy of Depression. New York, NY: Guilford Press.
39. Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
40. Hickman D, Vasavanonda S, Nequist G, Colletti L, Kati WM, et al. (2004) Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother 48(8): 2911-7.
41. Capparelli EV, Holland D, Okamoto C, Graqq B, Durelle J, et al. (2005) Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19: 949-952.
42. Letendre SL, van den Brande G, Hermes A, Woods SP, Durelle J, et al. (2007) Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 45: 151 1-7.
43. Letendre S, (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19(4): 137-142.
44. Paton N, Meynard JL, Pulido F, Arenas-Pinto A, Girard PM, et al. (2011) Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. AIDS 25(3): 393-4.
45. Marra C, Zhao Y, Clifford D, Letendre S, Evans S, et al. (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23: 1359-1366.
46. Bunupuradah T, Chetchotisakd P, Jirajariyavej S, Munsakul W, Jirajariyavet S, et al. (2012) Neurocognitive Impairments in Patients Using Lopinavir/ritonavir Monotherapy vs. Lopinavir/ritonavir-based HAART. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, USA. Poster 479.
47. Pulido F, Delgado R, Arranz A, Rubio R, Pasquau J, et al. (2008) Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial. 48th ICAAC. 25-28 October 2008, Washington DC, USA. Poster H-1240.
48. ClinicalTrials.gov website. Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT). Available: http://clinicaltrials.gov, identifier NCT01230580. Accesed 2012 Oct 12.
49. ClinicalTrials.gov website. A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients with Undetectable Plasma HIV-1 RNA on Current Treatment (PROTEA). Available: http://clinicaltrials.gov, identifier NCT01448707. Accesed 2012 Oct 12.